|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **No-SUD** | **AUD only** | **CUD only** | **Psychostimulant use disorder+** | **Poly-SUD+** |
| **Baseline****N=227 (4 missing data on Baseline SUD status)** | 103 | 14 | 53 | 36 (includes 31 poly-SUD) | 48 |
| PANSS positive | 18.9(6.47) | 16.8(7.61) | 18.9(5.45) | 20.1(6.09) | 20.4(5.47) |
| PANSS negative | 20.8(5.69) | 19.0((7.42) | 19.6(4.39) | 20.2(4.14) | 20.9(4.05) |
| PANSS general | 36.0(7.58) | 32.1((7.64) | 34.8(7.16) | 35.7(6.10) | 36.0(6.31) |
| PANSS total | 75.7(16.8) | 67.9(19.0) | 73.3(13.50) | 76.0(13.24) | 77.2(13.1) |
| CDS | 6.1(3.64) | 5.1(4.61) | 5.5(4.09) | 5.4(3.71) | 5.5(3.34) |
| QoL | 49.2(22.74) | 57.2(23.96) | 49.0(21.36) | **37.9****(17.85)\*\*** | **39.7****(19.08)\*** |
| SOFAS | 35.8(13.74) | 34.3(11.58) | 32.3(10.86) | **29.9****(9.96)\*** | 32.9(12.37) |
| GAF | 33.0(12.03) | 31.4(9.89) | **28.7****(8.21)\*** | 29.4(10.87) | 30.7(11.58) |
| Work or study, % | 47.6 | 50.0 | 49.1 | **25.0\*** | **22.9\*\*** |
| Good medication compliance at 3 months, % | 88.1 | 78.6 | 84.9 | 75.0 | 80.9 |
| Treatment order at 3 months, % | 3.9 | 0.0 | 5.7 | 2.8 | 4.2 |
| Long-acting, injectable antipsychotic medication at 3 months, % | 9.8 | 0.0 | 9.4 | 25.0 | 19.1 |

**Supplementary Table 1. Baseline symptoms and functioning**

Notes. PANSS: Positive and Negative Symptoms Scale; CDS: Calgary Depression Scale; QoL: quality of life; SOFAS: Social and Occupational Functioning Scale; GAF: global assessment of functioning

+The poly-SUD and psychostimulant use disorder groups overlap (31 patients are included in both groups)

Data are means (SD) unless otherwise stated

. \*Significant differences between the substance misusing and no-SUD groups, p<0.05; \*\*Significant differences between the substance misusing and no-SUD groups, p<0.01